Bernd Liepold
28Patents
6h-index
55Co-inventors
72Inventor score
Filing activity: Sep 18, 1999 → Jul 26, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6599528B1 | Mechanically stable pharmaceutical presentations form containing liquid or semisolid surface-active substances | Human Necessities | 33 | Expired |
| US6599931B1 | Test system for characterizing the compatibility of bioactive substances and polyvinylpyrrolidone | Human Necessities | 13 | Expired |
| US8475842B2 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Human Necessities | 13 | Active |
| US9060986B2 | Delivery system for sustained release of a calcium-channel blocking agent | Human Necessities | 13 | Active |
| US8025899B2 | Solid pharmaceutical dosage form | Human Necessities | 10 | Active |
| US8268349B2 | Solid pharmaceutical dosage form | Human Necessities | 9 | Active |
| US11633396B2 | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one | Human Necessities | 5 | Active |
| US9333204B2 | Solid antiviral dosage forms | Human Necessities | 5 | Active |
| US8686026B2 | Solid compositions | Human Necessities | 4 | Active |
| US9744170B2 | Solid antiviral dosage forms | Human Necessities | 3 | Active |
| US8377952B2 | Solid pharmaceutical dosage formulation | Human Necessities | 3 | Active |
| US8399015B2 | Solid pharmaceutical dosage form | Human Necessities | 2 | Active |
| US8691878B2 | Solid pharmaceutical dosage form | Human Necessities | 2 | Active |
| US9642796B2 | Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor | Human Necessities | 2 | Active |
| US8333990B2 | Solid pharmaceutical dosage form | Human Necessities | 1 | Active |
| US9078921B2 | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same | Human Necessities | 1 | Active |
| US11975001B2 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Human Necessities | 0 | Active |
| US12178816B2 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Human Necessities | 0 | Active |
| US10463739B2 | Solid retard formulations based on solid dispersions | Human Necessities | 0 | Active |
| US10653625B2 | Production of dosage forms comprising a solid dispersion of a microcrystalline agent | Human Necessities | 0 | Active |
| US9402909B2 | Pharmaceutical dosage form comprising polymeric carrier composition | Human Necessities | 0 | Active |
| US8293374B2 | Test system for evaluating the compatibility of biologically active substances with copolymers | Emerging Cross-Sectional Technologies | 0 | Active |
| US9594073B2 | Test solvent for evaluating the compatibility of biologically active substances and graft copolymers | Chemistry; Metallurgy | 0 | Active |
| US9616130B2 | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same | Human Necessities | 0 | Active |
| US10105365B2 | Solid antiviral dosage forms | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.